HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDB Supplements Next On FDA's Investigational New Drug Warning List

This article was originally published in The Rose Sheet

Executive Summary

The agency published warnings to four firms marketing supplements containing CDB ingredients with claims to treat or cure cancer made in statements including testimonials on their websites for products varying from oils, capsules, tinctures and lotions to snacks including gummies and lollipops.


Related Content

It's Complicated: FDA Prohibits CBD In Supplements, Enforcement Priority On Disease Claims
SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill
CBD Cancer Claim Gets NAD Attention: Health And Wellness News
Keeping Track: New MCL Treatment Calquence, Submissions Galore, And A Breakthrough Designation For GSK
SARMs Spells Latest 'Synthetic Steroids' FDA Finds In Supplements
Cannabinoid Market Snapshot: GW's Epilepsy Success Bodes Well
FDA's Initial IND Warnings For CBD Supplements Could Ignite Regulatory Test
Cannabis Supplements’ Cancer Claims Spark FDA Warnings, Policy Point


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts